INTRODUCTION
============

Cholesterol is an essential constituent of biological membranes. Structurally, cholesterol has a single hydroxyl as the sole polar component, four rings, and a short alkyl chain, whereas most other lipids, such as glycerophospholipids and sphingolipids, are composed of large polar head groups and two long hydrocarbon chains ([@B45]; [@B14]). The unique chemical structure of cholesterol allows it to be absorbed into and extracted from membranes easily ([@B30]). Cholesterol substantially affects the biophysical properties of membranes because it is able to pack against the acyl chains of phospholipids, reduce membrane permeability, and facilitate the formation of liquid-ordered domains in membranes ([@B11]; [@B29]; [@B6]). The abundance and distribution of cholesterol within membranes are tightly controlled by complex homeostatic mechanisms ([@B26]; [@B13]; [@B14]).

Understanding the intracellular dynamics of cholesterol is critical because the proper distribution among the plasma membrane and cellular organelle membranes is important for cellular function ([@B46]; [@B21]; [@B39]). Cholesterol distribution among cellular compartments and within the membrane is heterogeneous ([@B14]). The plasma membrane is the largest cholesterol pool in the cell and contains ∼60% of total cellular cholesterol in cells such as fibroblasts ([@B19]). Cholesterol can flip rapidly between two membrane leaflets in a bilayer, and it has been shown that the half-time is \<1 s in erythrocytes ([@B17]; [@B43]). Cholesterol is also highly enriched in the endocytic recycling compartment (ERC), which can contain ∼30--35% of cellular cholesterol ([@B9]). In contrast, the endoplasmic reticulum (ER), which is the central organelle in maintaining cholesterol homeostasis, has relatively low cholesterol content ([@B21]; [@B26]; [@B14]). This creates a paradigm in which cholesterol levels sensed in the ER reflect the cholesterol distribution in other organelles, such as the plasma membrane and endosomes, and so there must be a mechanism for rapid redistribution of cholesterol among these organelles ([@B13]; [@B14]).

Several lines of evidence indicate that nonvesicular transport plays an important role in maintaining the correct distribution of cholesterol among organelles ([@B9]; [@B23]; [@B21]; [@B27]). Cholesterol can be incorporated into transport vesicles that carry membrane components from one organelle to another. However, this is not the sole pathway of sterol and lipid transport because newly synthesized sterols can be transported from the ER to the plasma membrane when vesicular trafficking is inhibited by either genetic or pharmacological intervention ([@B44]). This strongly suggests that a large fraction of cholesterol transport is mediated by nonvesicular, carrier-mediated transport mechanisms, but the mechanisms are poorly understood ([@B9]).

Several proteins are recognized as soluble sterol transfer proteins (STPs; [@B32]; [@B1]; [@B13]). STPs can directly interact with membrane compartments to extract sterol from one membrane and deliver it to another ([@B32]; [@B1]; [@B2]). However, in many cases, the precise role and function of these proteins in cellular sterol homeostasis are undetermined ([@B26]; [@B14]). Among STPs, the steroidogenic acute regulatory protein (StAR)--related lipid-transfer (START) domain (STARD) family is involved in several aspects of intracellular lipid trafficking ([@B41]; [@B13]). STARD4 has been implicated as an important sterol transport protein involved in maintaining cholesterol homeostasis ([@B40]; [@B27]). Overexpression of STARD4 increases cholesteryl ester accumulation in lipid droplets in an acyl-CoA:cholesterol acyl-transferase (ACAT)--dependent manner ([@B36]; [@B7]), and its expression is controlled at the transcriptional level by sterols ([@B41]).

Cholesterol transport can be studied by introduction of radioactive sterols or precursors into cells, but this method is indirect and requires stringent purification of organelles, as well as demonstration that cholesterol does not redistribute during the purification process ([@B5]; [@B9]; [@B14]). Alternatively, fluorescent sterols provide an opportunity for directly imaging sterol trafficking in live cells ([@B4]; [@B24]; [@B14]). Unlike synthetic cholesterol derivatives that have large fluorophores that can influence their interaction with other membrane components, dehydroergosterol (DHE) is a naturally occurring fluorescent sterol whose chemical structure is similar to that of cholesterol ([@B24]; [@B14]). Many studies have shown that DHE is generally a faithful mimic of cholesterol in model and biological membranes ([@B28]; [@B9]; [@B12]).

Previous studies from our laboratory used DHE and fluorescence recovery after photobleaching (FRAP) to measure sterol delivery from the plasma membrane to the ERC ([@B9]). After photobleaching, the DHE recovery in the ERC was reported to have a half-time of ∼2--3 min ([@B9]; [@B7]). However, only 40--50% of the ERC fluorescence was recovered, for unknown reasons ([@B9]; [@B7]). The DHE delivered to the ERC was mainly from the plasma membrane, which is the largest pool of cellular cholesterol. The recovery rate of DHE to the ERC was not greatly affected by ATP depletion, indicating that the transport was mainly nonvesicular ([@B9]). In agreement with this hypothesis, the rate of sterol delivery to the ERC was increased due to increasing cellular cholesterol carriers, either by microinjection of methyl-β-cyclodextrin (MCD) or overexpression of STARD4 ([@B27]). Under both of these conditions, the relative distribution of sterol in the plasma membrane and ERC was not greatly altered, suggesting that these organelles are near equilibrium in their cholesterol content ([@B26]; [@B27]; [@B14]).

The rate of sterol efflux from the ERC to the plasma membrane was previously studied using excess extracellular MCD ([@B9]). Of interest, this study showed that transport of DHE from the ERC to plasma membrane was inhibited by ATP depletion, indicating that vesicular transport out of, but not into, the ERC is a major contributor to sterol transport kinetics ([@B10]). Of note, the study also found that the entire cholesterol pool was mobile, but the rate of transfer from the ERC to the plasma membrane was nearly 10-fold slower than transfer to the ERC ([@B9]).

Although previous studies of sterol trafficking were insightful, they had several limitations and shortfalls. For instance, DHE is weakly fluorescent and is susceptible to photobleaching ([@B24]). This limits the number of time points that can be sampled before photobleaching of the probe ([@B9]). In addition, in previous FRAP studies, incomplete recovery prevented accurate and complete modeling of sterol transport from the plasma membrane to the ERC ([@B9]; [@B27]; [@B7]). Finally, efflux studies were limited due to cellular toxicity when using high concentrations of MCD ([@B9]).

In this study, we report detailed kinetics of sterol transport between the plasma membrane and the ERC by addressing many of the limitations of previous studies. With access to sensitive imaging cameras, we imaged DHE-labeled living cells with low illumination, which minimizes photobleaching and allows repeated measurements for up to 1 h. Compared with previous studies ([@B9]; [@B27]; [@B7]), we redesigned the FRAP method to enable full recovery of DHE fluorescence. We implemented an efflux method that uses a large exogenous cholesterol pool with hydroxypropyl cyclodextrin (HPCD)--cholesterol complexes to rapidly exchange with DHE at the plasma membrane. These new methods allow us to obtain detailed kinetic information describing sterol transport between the plasma membrane and the ERC because for the first time sterol transport from the plasma membrane to the ERC and efflux from the ERC to the plasma membrane can be modeled as single-rate processes. For the first time, we report bidirectional sterol transport kinetics between the ERC and plasma membrane and show that STARD4 is critical for these processes.

RESULTS
=======

Cholesterol transport between ERC and plasma membrane
-----------------------------------------------------

To measure the rate of cholesterol transport between the ERC and the plasma membrane, we assessed the trafficking kinetics of the fluorescent sterol DHE ([@B4]) in human osteosarcoma (U2OS) cells stably expressing the scavenger receptor A (U20S-SRA; [@B20]). These cell were used previously to study sterol transport ([@B27]) and allow cholesterol loading through SRA. To measure the bidirectional transport of DHE between the plasma membrane and the ERC, shown schematically in [Figure 1](#F1){ref-type="fig"}, we used FRAP of the ERC and developed a novel DHE efflux assay to measure export from the ERC based on rapid exchange of DHE with cholesterol at the plasma membrane.

![Schematic of fluorescence method to study sterol transport between plasma membrane and ERC. U2OS-SRA cells are loaded with DHE complexed to MCD for 1 min. DHE is allowed to equilibrate among cellular membranes for 120 min. At steady state, DHE is enriched in the ERC and plasma membrane (yellow). The ERC is identified using fluorescently labeled Tf (red outline). (A) To monitor transport to the ERC, the ERC is photobleached, and the FRAP of DHE is recorded. (B) To monitor transport from the ERC, cellular medium is exchanged with medium containing red blood cells (RBCs) and HPCD--cholesterol complex. As fluorescent DHE is exchanged at the plasma membrane for nonfluorescent cholesterol, the fluorescence signal of the ERC decreases over time.](1111fig1){#F1}

MCD--DHE complexes were prepared as described previously ([@B38]). Cells were labeled for 1 min with 25 mM MCD--5 mM DHE complex. In contrast to previous studies ([@B9]; [@B27]), cells were chased for 2 h in chase medium (see *Materials and Methods*) to allow the sterol to equilibrate among membranes. An ACAT inhibitor, 30 µg/ml Sandoz 58--035, was used during this period to prevent esterification and ensure that the entire DHE pool remained mobile during the experiment. In the last 20 min, the cells were labeled with fluorescent transferrin to identify the ERC.

To measure the sterol transport from the plasma membrane to the ERC, we used FRAP and monitored the recovery of DHE fluorescence in the ERC. Images were analyzed as described previously ([@B9]; [@B27]; [@B7]), with minor alterations (see *Materials and Methods* for details). In addition to measuring the DHE fluorescence in ERC and the entire cell fluorescence, a region of the plasma membrane adjacent to the ERC that was photobleached was also analyzed to account for diffusion of DHE in the plasma membrane into the photobleached region containing both plasma membrane and ERC. Taking the plasma membrane recovery rate into account, we can accurately measure DHE fluorescence recovery in the ERC.

In control U2OS-SRA cells, photobleaching of DHE in the ERC resulted in ∼30% fluorescence being recovered in 10 min, with a half-time for full recovery (*t*~1/2~) of 14.5 ± 1.5 min ([Figure 2, A and C](#F2){ref-type="fig"}, and Supplemental Figure S1). All kinetics results are summarized in [Table 1](#T1){ref-type="table"}. All of the kinetic studies in this article were modeled as single first-order rate processes with 100% recovery. In some cases, deviations from the fit to a single rate process can be seen, but we have not attempted to fit the data to more complex models. A composite set of control data from multiple experiments is shown in all kinetics graphs.

![Bidirectional sterol transport. For both FRAP and efflux experiments, U2OS-SRA cells were labeled with DHE for 1 min and equilibrated for 120 min. In the last 20 min, cells were incubated with 20 μg/ml Tf--Alexa 546 at 37°C in medium 2/glucose to identify the ERC. Cells were maintained at 37°C. (A) For FRAP recovery to the ERC, an image was taken before photobleaching. DHE in the ERC was photobleached (yellow arrow), and images were taken every 30 s. (B) FRAP measurements for control, LPDS, and cholesterol-overloaded cells. Control, *t*~1/2~ = 14.5 ± 1.5 min; LPDS, *t*~1/2~ = 10.4 ± 1.3 min; overloading, *t*~1/2~ = 3.8 ± 0.6 min. (C) To record the loss of DHE from the ERC, an image was taken before exchanging with efflux medium. Images were analyzed as described in *Materials and Methods*. Cells were maintained at 37°C. Scale bar, 10 μm. Where indicated, cellular cholesterol levels were decreased or increased by overnight incubation with LPDS medium or acute treatment with HPCD--cholesterol complex, respectively. (D) DHE efflux curves for control, LPDS, and cholesterol-overloaded cells. Control, *t*~1/2~ = 14.9 ± 0.9 min; LPDS, *t*~1/2~ = 14.3 ± 1.3 min; overloading, *t*~1/2~ = 5.8 ± 0.3 min. Each data point is derived from an average of at least eight experiments (±SE). Data are fitted to single-exponential curves.](1111fig2){#F2}

###### 

Half-times (*t*~1/2~) of FRAP and efflux experiments.

                                        FRAP *t*~1/2~ (min ± SE)   *R*-square   Efflux *t*~1/2~ (min ± SE)   *R*-square
  ------------------------------------- -------------------------- ------------ ---------------------------- ------------
  Control, 10 min                       14.5 ± 1.5                 0.85         14.9 ± 0.9                   0.99
  Control, 30 min                       12.5 ± 3.4                 0.99                                      
  LPDS                                  10.4 ± 1.3                 0.99         14.3 ± 1.3                   0.98
  Overload                              3.8 ± 0.6                  0.98         5.8 ± 0.3                    0.99
  Energy depletion                      21.2 ± 3.2                 0.99         18.3 ± 1.1                   0.98
  Energy depletion, 30 min              24.2 ± 1.8                 0.94                                      
  HPCD                                  1.3 ± 0.3                  0.98         4.1 ± 0.4                    0.99
  STARD4                                4.3 ± 0.5                  0.97         4.9 ± 0.6                    0.99
  CRISPR SD4 KD                         22.4 ± 2.1                 0.98         20.2 ± 0.4                   0.96
  CRISPR SD4 + mC-FKBP-SD4              11.0 ± 1.6                 0.98         12.5 ± 0.4                   0.98
  CRISPR SD4 + mC-FKBP-SD4 + MitoTrap   19.7 ± 1.5                 0.96         19.1 ± 0.5                   0.96
  CRISPR SD4 + W108D mC-FKBP-SD4        21.9 ± 1.5                 0.96         19.0 ± 0.2                   0.95
  CRISPR SD4 + energy depletion         24.1 ± 1.3                 0.99         24.8 ± 0.3                   0.94

Half-times (*t*~1/2~) for FRAP and efflux experiments (±SE) were determined by fitting curves to a single exponential. The *R*-square of the fit was determined using GraphPad Prism software.

To determine the rate of cholesterol transport from the ERC to the plasma membrane, we incubated U2OS-SRA cells in exchange medium that contained ∼10^9^ sheep red blood cells, which acts as an exogenous cholesterol pool, plus partially cholesterol loaded HPCD. This allows for rapid exchange of fluorescent DHE for nonfluorescent cholesterol at the plasma membrane, resulting in reduction of DHE fluorescence in the cell. Incubation of cells with exchange medium did not result in toxicity as monitored by propidium iodide staining (unpublished data) or alterations to cellular cholesterol levels (Supplemental Figure S2). Similar to the analysis of FRAP experiments, efflux images were analyzed by examining loss of DHE fluorescence from the ERC and an adjacent plasma membrane region. This analysis ensures that we measure the loss of fluorescence in the ERC and that the plasma membrane fluorescence is accounted for in the analysis.

After placement of cells into exchange medium, DHE in the plasma membrane is exchanged with nonfluorescent cholesterol with *t*~1/2~ ≈ 2 min (Supplemental Figures S5, S7, S11, S13, S18, and S20). Because the plasma membrane pool of DHE exchanges rapidly, there is very little DHE transport from the plasma membrane back to the ERC during efflux experiments. Under control conditions, DHE fluorescence in the ERC was reduced with a *t*~1/2~ = 14.9 ± 0.9 min after the start of exchange with cholesterol at the plasma membrane ([Figure 2, C and D](#F2){ref-type="fig"}, blue, and Supplemental Figure S1). Using both the FRAP and efflux methods, we were able to accurately determine the *t*~1/2~ of sterol transport to and from the ERC to be ∼12--15 min.

Intracellular cholesterol levels affect cholesterol transport
-------------------------------------------------------------

To evaluate the role of intracellular cholesterol levels in modulating cholesterol transport, we determined the DHE trafficking kinetics in U2OS-SRA cells after cholesterol depletion or transient overloading ([Figure 2](#F2){ref-type="fig"}). After metabolic depletion by overnight incubation in medium with lipoprotein-depleted serum (LPDS) and the HMG-CoA reductase inhibitor mevastatin, cellular cholesterol levels were reduced by ∼25% compared with control cells (Supplemental Figure S3). Of interest, after metabolic depletion of cellular cholesterol, DHE was trafficked to and from the ERC with half-times similar to or slightly faster than in controls, 10.4 ± 1.3 and 14.3 ± 1.3 min ([Figure 2](#F2){ref-type="fig"} and Supplemental Figure S1, red), respectively. Cholesterol overloading was accomplished by transient treatment with HPCD--cholesterol complex for 5 min. This treatment increased cholesterol levels by ∼20% (Supplemental Figure S3). The increased cellular cholesterol levels resulted in rapid DHE transport both to and from the ERC with *t*~1/2~ = 3.8 ± 0.6 and 5.8 ± 0.3 min, respectively ([Figure 2](#F2){ref-type="fig"} and Supplemental Figure S1, green). These data indicate that moderate increases in cholesterol levels increase the rate constant for sterol transport, but moderate reductions in cholesterol do not greatly alter the transport rate constant.

Role of ATP-dependent transport in sterol transport rates
---------------------------------------------------------

Intracellular transport of cholesterol between organelles is mediated by both vesicular and nonvesicular transport mechanisms ([@B21]; [@B26]; [@B14]). Because vesicular transport is ATP dependent, we used ATP depletion by treatment with sodium azide and 2-deoxyglucose to inhibit vesicular transport between the ERC and the plasma membrane ([Figure 3](#F3){ref-type="fig"} and Supplemental Figures S4 and S5). We verified that endocytosis of fluorescently labeled transferrin (Tf) had been stopped by this treatment (unpublished data). After energy depletion, DHE trafficked to the ERC with a *t*~1/2~ = 21.2 ± 3.2 min and out of the ERC with a *t*~1/2~ = 18.3 ± 1.1 min ([Figure 3](#F3){ref-type="fig"} and Supplemental Figure S4).

![Role of vesicular sterol transport. U2OS-SRA cells were treated with energy depletion (ED) medium to deplete cellular ATP levels. (A) FRAP measurements for control and ED. Control, *t*~1/2~ = 14.5 ± 1.5 min; ED, *t*~1/2~ = 21.2 ± 3.2 min. (B) DHE efflux curves for control and ED. Control, *t*~1/2~ = 14.9 ± 0.9 min; ED, *t*~1/2~ = 18.3 ± 1.1 min. (C) Extended FRAP measurement for control and ED U2OS-SRA cells. Control, *t*~1/2~ = 12.5 ± 3.4 min; ED, *t*~1/2~ = 24.2 ± 1.8 min. Each data point is derived from an average of at least eight experiments (±SE). Data are fitted to single-exponential curves.](1111fig3){#F3}

Because the recovery *t*~1/2~ exceeded the duration of the fluorescence imaging, we extended the measured recovery time from 10 to 30 min to ensure that the recovery time was measured accurately. After 30 min, ∼90% of the DHE in the ERC of control cells had recovered, compared with only ∼40% recovered in energy-depleted cells. Consistent with the 10-min FRAP data, in control cells, DHE trafficked to the ERC with a *t*~1/2~ = 12.5 ± 3.4 min ([Figure 3C](#F3){ref-type="fig"} and Supplemental Figure S4, blue), and in ATP-depleted cells, t~1/2~ = 24.2 ± 1.8 ([Figure 3C](#F3){ref-type="fig"} and Supplemental Figure S4, red).

Increasing levels of sterol transporters cause faster sterol transport
----------------------------------------------------------------------

Previous work demonstrated that sterol transport is maintained in large part by nonvesicular mechanisms ([@B21]; [@B7]; [@B14]). However, it has been impossible to quantify accurately the portion of sterol transport that is maintained by specific nonvesicular mechanisms, due to incomplete DHE recovery in previous experiments ([@B9]; [@B27]; [@B7]). Using the improved methods described here, we examined the role of soluble sterol transporters in moving sterol between the ERC and the plasma membrane ([Figure 4](#F4){ref-type="fig"}). As a first test, we increased the number of soluble sterol carrier levels by microinjection of a relatively sterol-specific β-cyclodextrin ([@B16]; [@B48]), HPCD. When U2OS-SRA cells were microinjected with (1--3) × 10^9^ molecules of HPCD, nearly equal to the number of cholesterol molecules in a cell ([@B22]), there was a substantial increase in the rate of sterol transport both to and from the ERC, with *t*~1/2~ = 1.3 ± 0.3 and 4.1 ± 0.4 min, respectively ([Figure 4, A and B](#F4){ref-type="fig"}, and Supplemental Figures S6 and S7). This is in general agreement with accelerated sterol transport observed when cells were microinjected with MCD ([@B27]).

![Microinjected HPCD and STARD4 overexpression enhances bidirectional sterol transport. HPCD and rhodamine--dextran were microinjected immediately before labeling of cells with DHE. U2OS-SRA cells were transfected with GFP-STARD4 for 18 h before the experiment. (A) FRAP measurements for single cells microinjected with HPCD or transfected with GFP-STARD4. Control, *t*~1/2~ = 14.5 ± 1.5 min; HPCD (1 × 10^9^ molecules/cell), *t*~1/2~ = 1.3 ± 0.3 min; GFP-STARD4, *t*~1/2~ = 4.3 ± 0.5 min. (B) DHE efflux curves for cells microinjected with HPCD or transfected with GFP-STARD4. Control, *t*~1/2~ = 14.9 ± 0.9 min; HPCD (0.5 × 10^9^ molecules/cell), *t*~1/2~ = 4.1 ± 0.4 min; GFP-STARD4, *t*~1/2~ = 4.9 ± 0.6 min. Each data point is derived from an average of at least 10 experiments (±SE). Data are fitted to single-exponential curves.](1111fig4){#F4}

To evaluate quantitatively the specific role of STARD4, we overexpressed it transiently. In control U2OS-SRA cells, there are ∼250,000 STARD4 copies per cell (Supplemental Figure S8). Transient overexpression of GFP-STARD4 increases the number of STARD4 molecules by fourfold over endogenous levels (Supplemental Figure S8), and this accelerates the rate of sterol transport to and from the ERC with *t*~1/2~ = 4.3 ± 0.5 and 4.9 ± 0.6 min, respectively ([Figure 4, A and B](#F4){ref-type="fig"}, and Supplemental Figures S6 and S7). This is consistent with a report ([@B27]) in which overexpression of STARD4 resulted in accelerated sterol transport to the ERC compared with control cells. These results indicate that 10^6^ STARD4 molecules per cell are nearly as effective as 10^9^ HPCD molecules in transporting cholesterol to and from the ERC.

Reduction of STARD4 slows sterol transport between ERC and plasma membrane
--------------------------------------------------------------------------

STARD4 is transcriptionally regulated by the sterol-responsive element--binding protein-2 (SREBP-2) and has been implicated as an important sterol carrier ([@B27]; [@B7]; [@B13]). However, the exact function of STARD4 in cholesterol transport and homeostasis is not well understood ([@B34]). To address this, we used clustered regularly interspaced short palindromic repeats (CRISPR) to disrupt the genomic copy of STARD4 in U2OS-SRA cells (Supplemental Table S1). To minimize the complications that occur after stable knockdown of STARD4 ([@B27]), we transiently transfected U2OS-SRA with CRISPR constructs to disrupt the STARD4 gene and examined the effect 18 h later ([Figure 5](#F5){ref-type="fig"}). Under these conditions, cells expressing the SD4 CRISPR constructs were viable and had comparable cholesterol levels to control cells but had ∼95% lower STARD4 protein levels (Supplemental Figure S9). Genomic disruption of STARD4 slowed sterol transport both to and from the ERC with *t*~1/2~ = 22.4 ± 2.1 and 20.2 ± 0.4 min, respectively ([Figure 5, A and B](#F5){ref-type="fig"}, and Supplemental Figures S10 and S11). Of importance, the loss of STARD4 did not alter general vesicular transport, as the rate of Tf efflux from the ERC in both SD4 CRISPR knockdown and control cells was similar (Supplemental Figure S12).

![Depletion of STARD4 slows sterol transport between ERC and plasma membrane. U2OS-SRA cells were transfected with GFP-Cas9 (STARD4 CRISPR) constructs for 18 h before the experiment. (A) FRAP measurements for single cells expressing STARD4 CRISPR constructs. Control, *t*~1/2~ = 14.5 ± 1.5 min; SD4 CRISPR, *t*~1/2~ = 22.4 ± 2.1 min. (B) DHE efflux curves for cells expressing STARD4 CRISPR constructs. Control, *t*~1/2~ = 14.9 ± 0.9 min; SD4 CRISPR, *t*~1/2~ = 20.2 ± 0.4 min. Each data point is derived from an average of at least 11 experiments (±SE). Data are fitted to single-exponential curves.](1111fig5){#F5}

To validate further the importance of STARD4 in sterol transport, we took advantage of a methodology that rapidly depletes soluble proteins by irreversible recruitment to organelles such as mitochondria ([@B15]; [@B35]). We expressed an mCherry-FKB-STARD4 in U2OS-SRA cells that also expressed a mitochondrial protein (Mito; [@B35]) that contains an FRB domain. In the absence of rapamycin, FKBP-STARD4 is diffusely expressed throughout the cytosol. On rapamycin-induced FKBP-FRB dimerization, mCherry-FKB-STARD4 was rapidly depleted from the cytosol and targeted to mitochondria (Supplemental Figure S13). As a result of STARD4 recruitment to the mitochondria, it looks by conventional epifluorescence microscopy as though the mitochondria have become enriched in sterol (Supplemental Figures S13 and S14). However, confocal imaging of rapamycin-treated cells that have STARD4 recruited to the mitochondria shows that the enrichment of sterol is not in mitochondria but in another membrane compartment (Supplemental Figure S15).

The mCherry-FKBP-STARD4 was able to carry out sterol transport between the ERC and the plasma membrane. We measured FRAP and efflux *t*~1/2~ values of 11.0 ± 1.6 and 12.5 ± 0.4 min, respectively, in U2OS-SRA cells expressing mCherry-FKB-STARD4 in which endogenous STARD4 had been removed using CRISPR ([Figure 6, A and B](#F6){ref-type="fig"}, and Supplemental Figures S13 andS16).

![Expression of wild-type, cytosolic-localized STARD4 restores sterol transport between ERC and plasma membrane. U2OS-SRA cells were transfected with mCherry-FKBP-STARD4 with or without MitoTrap 48 h before the experiment. STARD4 CRISPR constructs were transfected for 18 h before the experiment. To redistribute STARD4 from the cytosol to the mitochondria, cells expressing MitoTrap were treated with 1 μM rapamycin for 10 min before imaging. After rapamycin treatment, cells were washed, and fresh medium 2 was added. (A) FRAP measurements for single cells expressing mCherry-FKBP-STARD4 and MitoTrap in cells expressing STARD4 CRISPR constructs. Control, *t*~1/2~ = 14.5 ± 1.5 min; SD4 CRISPR, *t*~1/2~ = 11.0 ± 1.6 min; SD4 CRISPR + SD4 + Mito, *t*~1/2~ = 19.7 ± 1.5 min. (B) DHE efflux curves for cells expressing mCherry-FKBP-STARD4 and MitoTrap in cells expressing STARD4 CRISPR constructs Control, *t*~1/2~ = 14.9 ± 0.9 min; SD4 CRISPR, *t*~1/2~ = 12.5 ± 0.4 min; SD4 CRISPR + SD4 + Mito, *t*~1/2~ = 19.1 ± 0.3 min. Each data point is derived from an average of at least 10 experiments (±SE). Data are fitted to single-exponential curves.](1111fig6){#F6}

U2OS-SRA cells expressing STARD4 CRISPR, mCherry-FKBP-STARD4, and MitoTrap were treated with rapamycin, leading to redistribution of STARD4 from the cytosol to the mitochondria. The depletion of STARD4 from the cytosol results in reduced sterol transfer between the ERC and plasma membrane, with FRAP and efflux *t*~1/2~ = 19.7 ± 1.5 and 19.1 ± 0.3 min, respectively ([Figure 6, A and B](#F6){ref-type="fig"}, and Supplemental Figure S16).

Functional STARD4 is required for efficient sterol transport between the ERC and the plasma membrane
----------------------------------------------------------------------------------------------------

Previous work has shown that several regions of STARD4 are required for transfer of sterol between liposomes ([@B27]; [@B12]). Specifically, introduction of an aspartic acid at the apex of the omega-1 loop resulted in attenuated sterol transfer between liposomes and reduced interaction with membranes ([@B12]). We examined whether a W108D mutation in the omega-1 loop of STARD4 reduced the sterol transfer kinetics in cells ([Figure 7](#F7){ref-type="fig"}). Expression of a STARD4 construct with a W108D mutation in mCherry-FKBP-STARD4 did not restore sterol transport to and from the ERC in cells lacking endogenous STARD4. We observed FRAP and efflux *t*~1/2~ = 21.9 ± 1.5 and 19.0 ± 0.2 min, respectively ([Figure 7, A and B](#F7){ref-type="fig"}, and Supplemental Figures S17 and S18), showing that the described mechanism of STARD4 sterol transport between liposomes ([@B12]) also occurs in cells.

![Expression of omega-1 loop mutant (W108D) of STARD4 does not restore sterol transport. (A) U2OS-SRA cells were transfected with either wild-type or W108D mCherry-FKBP-STARD4 48 h before the experiment. STARD4 CRISPR constructs were transfected for 18 h before the experiment. FRAP measurements for cells expressing wild-type or W108D mCherry-FKBP-STARD4 in cells expressing STARD4 CRISPR constructs. Control, *t*~1/2~ = 14.5 ± 1.5 min; SD4 CRISPR + SD4, *t*~1/2~ = 11.0 ± 1.6 min; SD4 CRISPR + W108D SD4, *t*~1/2~ = 21.9 ± 1.5 min. (B) DHE efflux curves for cells expressing wild-type or W108D mCherry-FKBP-STARD4 in cells expressing STARD4 CRISPR constructs. Control, *t*~1/2~ = 14.9 ± 0.9 min; SD4 CRISPR + SD4, *t*~1/2~ = 12.5 ± 0.4 min; SD4 CRISPR + W108D SD4, *t*~1/2~ = 19.0 ± 0.2 min. Each data point is derived from an average of at least 10 experiments (±SE). Data are fitted to single-exponential curves.](1111fig7){#F7}

STARD4 is a major sterol transporter between the ERC and the plasma membrane
----------------------------------------------------------------------------

With the quantitative tools described here, we sought to determine the portion of sterol transport that is specifically mediated by STARD4. To accomplish this, we removed endogenous STARD4 using CRISPR and blocked vesicular transport by ATP depletion ([Figure 8, A and B](#F8){ref-type="fig"}, and Supplemental Figures S19 and S20). We then measured the rate constants for delivery to the ERC by FRAP or transport out of the ERC by the efflux assay ([Figure 8C](#F8){ref-type="fig"}) and plotted them against data described earlier for STARD4 CRISPR ([Figure 5](#F5){ref-type="fig"}) and energy depletion ([Figure 3](#F3){ref-type="fig"}). The combination of ATP depletion and knockout of STARD4 results in slow transport both to and from the ERC and plasma membrane, with *t*~1/2~ = 24.1 ± 1.3 and 24.8 ± 0.3 min, respectively ([Figure 8, A and B](#F8){ref-type="fig"}, and Supplemental Figures S19 and S20) These half-times are slower than those for either ATP depletion alone ([Figure 3](#F3){ref-type="fig"}) or STARD4 reduction by CRISPR ([Figure 5](#F5){ref-type="fig"}). Comparing the normalized rate constants of treatments to control cells, we find that ATP-independent transport accounts for nearly 75% of sterol transport between the ERC and plasma membrane. STARD4 accounts for ∼25% of all sterol transport and ∼33% of nonvesicular transport between these organelles ([Figure 8C](#F8){ref-type="fig"}).

![STARD4 is a major nonvesicular sterol transport protein. U2OS-SRA cells were transfected with STARD4 CRISPR constructs and/or treated with energy depletion (ED) medium. (A) FRAP measurements for cells expressing STARD4 CRISPR constructs with or without ED. Control, *t*~1/2~ = 14.5 ± 1.5 min; SD4 CRISPR, *t*~1/2~ = 22.4 ± 2.1 min; ED, *t*~1/2~ = 21.2 ± 3.2 min; SD4 CRISPR + ED, *t*~1/2~ = 24.1 ± 1.3 min. (B) DHE efflux measurements for cells expressing STARD4 CRISPR constructs with or without ED. Control, *t*~1/2~ = 14.9 ± 0.9 min; SD4 CRISPR, *t*~1/2~ = 20.2 ± 0.4 min; ED, *t*~1/2~ = 18.3 ± 1.1 min; SD4 CRISPR + ED, *t*~1/2~ = 24.8 ± 0.3 min. (C) Normalized sterol transfer rate constants for FRAP (red) and efflux (blue) experiments under control, ED, STARD4-CRISPR and CRISPR-ED conditions. Each data point is derived from an average of at least nine experiments (±SE). Data are fitted to single-exponential curves.](1111fig8){#F8}

DISCUSSION
==========

In this study, we developed greatly improved methods to monitor the trafficking of the fluorescent cholesterol analogue DHE ([@B4]) between the ERC and plasma membrane of living cells. Although previous work reported sterol transfer kinetics to the ERC using FRAP ([@B9]; [@B27]; [@B7]), the kinetic modeling was seriously incomplete because there was only partial recovery of the DHE fluorescence in the ERC. We identified two main causes of the incomplete recovery. First, previous studies allowed ∼15 min after incorporation of DHE into the plasma membrane before starting kinetic measurements. This was based on imaging showing that the distribution of DHE in the cells was apparently unchanged after a 15-min chase ([@B9]; [@B27]; [@B7]). Allowing a longer equilibration time (2 h in this study) gave slower rate constants for transport but allowed for full recovery of DHE fluorescence into the ERC. The second issue was that with previous imaging equipment, only ∼5--10 measurements could be made before photobleaching made measurements unreliable. With improved optics and cameras, we reduced the illumination intensity so that greater than 20 measurements could be made on each cell. With these improvements, all of our FRAP kinetic studies were modeled as single first-order rate processes with 100% recovery.

We also developed a novel method for measuring the kinetics of efflux of DHE from the ERC to the plasma membrane. Again, there had been previous efflux measurements ([@B9]), but they used relatively low concentrations (5 mM) of cholesterol-free MCD to extract DHE from the plasma membrane. Here we used 80 mM HPCD that was preequilibrated with sheep erythrocytes so that it did not change the total sterol content when incubated with cells. This high concentration of HPCD rapidly exchanged DHE in the PM for cholesterol with *t*~1/2~ = 2 min, and this made DHE transport from the ERC to the plasma membrane effectively irreversible, allowing us to measure the transport rates in this direction. These efflux transport rates were also modeled as single first-order rate processes that went to completion. Thus we were able to measure sterol transfer rate constants in both directions between the ERC and the plasma membrane.

Using these methods, we found that transfer between the ERC and the plasma membrane has *t*~1/2~ ≈ 12--15 min in both directions. This transport is slower than previous reports, in which recovery of the ERC after photobleaching occurred with *t*~1/2~ ≈ 3 min ([@B9]; [@B27]; [@B7]). However, unlike previous reports ([@B9]; [@B27]; [@B7]), in which only ∼40--50% of the sterol pool in the ERC was recovered, we obtained 100% recovery. It is not clear why longer equilibration times lead to slower rates of transport and higher mobile fractions. One possibility is that the DHE labeling protocol, which uses MCD--DHE complexes, perturbs the cells. We showed previously that the loading protocol does not significantly alter total cell cholesterol (Supplemental Figure S2), but MCD is also known to interact with some other lipids ([@B49]). It may take some time for the cells to recover from the perturbations due to loading with DHE.

Although multiple processes are responsible for sterol transport between the ERC and the plasma membrane, we found that transport kinetics could be modeled reasonably well in most cases by a single process, although there are likely several transport processes occurring simultaneously. This may be in part coincidental. Transport of a labeled sphingomyelin from the ERC to the plasma membrane of CHO cells by vesicle transport processes had a *t*~1/2~ ≈ 12 min ([@B25]), indicating that bulk lipid flow by vesicle transport on the recycling pathway occurs at this rate, which is comparable to the overall *t*~1/2~ we observe for vesicular and nonvesicular transport of sterol. With the accuracy of the present measurements, it would be difficult to resolve multiple rate constants from our data, but with further methodological advances, more detailed analysis may become feasible.

We can now examine the effects of various manipulations on rates of sterol transport. Increasing cellular cholesterol by ∼20% by brief incubation with cholesterol-loaded HPCD caused a threefold to fourfold increase in rate constants for DHE transport in either direction between the plasma membrane and the ERC ([Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). A 25% reduction of cholesterol after overnight growth in lipoprotein-depleted serum and treatment with a statin had a more modest effect on DHE transport rates, with no significant change in efflux to the plasma membrane and a slight increase in transport rate to the ERC. The asymmetric effects of increasing and decreasing cholesterol levels would be consistent with studies indicating that plasma membrane cholesterol is held at a level at which small increases in cholesterol concentration lead to large changes in its chemical potential (i.e., the chemical activity coefficient increases rapidly when cholesterol concentration is increased; [@B33]; [@B42]; [@B3]). Previous studies showed that even small elevations of cellular cholesterol above a threshold lead to large increases in cholesterol esterification by ACAT, which requires transport to the endoplasmic reticulum ([@B47]; [@B18]).

A substantial portion of sterol transport is mediated by nonvesicular transport mechanisms ([@B9]; [@B21]). Vesicle transport requires ATP, and in our cells, ATP depletion to levels that completely block Tf receptor endocytosis reduces the rate of transport between the ERC and the plasma membrane by only ∼25--33% ([Figure 8C](#F8){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). This suggests that ∼67--75% of the total sterol transport between these membranes is ATP independent and does not require vesicle transport.

We examined the role of a specific sterol transporter, STARD4, which has been implicated as an important sterol transporter in various cell types ([@B27]; [@B36]; [@B7]). Approximately fourfold increase in STARD4 expression led to approximately threefold increase in the rates of transport of DHE between the plasma membrane and the ERC ([Figure 4](#F4){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). This confirms that STARD4 can transport sterol very effectively in cells. Of note, the cholesterol distribution was not altered when levels of soluble sterol transporters were increased, suggesting that cellular membranes are near or at chemical equilibrium ([@B27]; [@B14]).

Previous work showed that transient knockdown of STARD4 resulted in altered cholesterol levels and sensing ([@B27]). We also found that long-term reduction of STARD4 levels to ∼20% of control levels by stable transfection with short hairpin RNA leads to large differences in cellular lipid content (D. B. Iaea, R. B. Chan, B. Zhou, R. Bareja, O. Elemento, G. Di Paolo, and F. R. Maxfield, unpublished data). To avoid these long-term effects, we used two approaches. First, we examined cells 18 h after disruption of the STARD4 gene with a CRISPR construct, which led to a 95% reduction in STARD4 protein. In these cells, sterol levels remained similar to control cells, but the distribution and transport between the ERC and the plasma membrane were perturbed. Comparing the rate constants for transport between the ERC and the plasma membrane indicates that STARD4 is a critical sterol transport protein and accounts for ∼25% of total and ∼33% of nonvesicular sterol transport ([Figure 8C](#F8){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). To achieve more rapid elimination of STARD4, we transfected SD4 CRISPR cells with a mCherry-FKB-STARD4 construct and a mitochondrial protein that contains an FRB domain. The transfection led to somewhat faster sterol transport than in control cells ([Table 1](#T1){ref-type="table"}), reflecting the expression levels of the STARD4 constructs. Addition of rapamycin ([Figure 6](#F6){ref-type="fig"}) caused ∼35% reduction in the sterol transport rate constants, very close to the reduction obtained with CRISPR disruption of STARD4. These data suggest that STARD4 is responsible for a substantial amount of sterol transport between the ERC and the plasma membrane.

There is a complex interplay of vesicular and nonvesicular transport mechanisms that act to maintain cholesterol distribution ([@B21]; [@B26]; [@B14]). This study reports bidirectional sterol transport kinetics between the ERC and the plasma membrane under various conditions. For the first time, we provide detailed sterol transfer kinetics between two major cholesterol-containing organelles and show that ∼66--75% of this sterol transport is performed by nonvesicular, soluble sterol transport proteins. Furthermore, we show that STARD4 accounts for ∼25% of total sterol transport and ∼33% of all nonvesicular transport between the plasma membrane and the ERC. Thus STARD4 is an important sterol transport protein involved in sterol transport between the ERC and plasma membrane.

MATERIALS AND METHODS
=====================

Materials
---------

Sheep red blood cells were purchased from Innovative Research (Novi, MI). Alexa labeling kits were purchased from Invitrogen. Human Tf and DHE were purchased from Sigma-Aldrich. All tissue culture supplies were purchased from Invitrogen. All other chemicals were from Sigma-Aldrich. The media used are as follows: medium 2 (150 mM NaCl, 5 mM KCl, 1 mM CaCl~2~, 1 mM MgCl~2~ and 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid \[HEPES\], pH 7.4); M2glucose (medium 2 containing 2 mg/ml glucose); chase medium (M2glucose containing 30 μg of Sandoz 58035); efflux medium (chase medium with 80 mM HPCD--cholesterol complex and ∼1 × 10^9^ sheep red blood cells/ml); and energy depletion medium (medium 2 with 15 μM NaN~3~ and 15 μM 2-deoxyglucose). Rabbit anti-STARD4 monoclonal (EPR17847-32) antibody was purchased from Abcam. Rabbit anti--pan actin polyclonal (AANO1-A) antibody was purchased from Cytoskeleton.

Cell culture and transfection
-----------------------------

U2OS-SRA is a modified human osteosarcoma cell line that expresses SRA ([@B20]). U2OS-SRA cells were grown at 37°C in a 5% CO~2~ humidified incubator in McCoy's 5A medium supplemented with 10% fetal bovine serum (FBS), 1 mg/ml Geneticin as a selection for SRA, 100 U/ml penicillin, and 100 μg/ml streptomycin. For STARD4 expression, U2OS-SRA cells were transiently transfected with pEGFP-C1-hSTARD4 using FuGENE 6 transfection reagent (Promega, Madison, WI) according to the manufacturer's instructions. To modulate STARD4 protein levels or localization, U2OS-SRA cells were transfected with STARD4 CRISPR-GFP (SD4 CRISPR), YFP-FRB-MitoTrap (Mito), and mCherry-FKBP-STARD4. For rapamycin-dependent redistribution of STARD4 to the mitochondria, cells were treated with 1 μM rapamycin for 10 min before FRAP and efflux experiments. All studies for transient transfection were performed 18 h after transfection unless stated otherwise. Cells for wide-field microscopy were plated on 35-mm plastic dishes, the bottoms of which were replaced with poly-[d]{.smallcaps}-lysine--coated coverslips.

Fluorescence labeling and immunofluorescence
--------------------------------------------

Human Tf (Sigma-Aldrich) was iron loaded and purified by Sephacryl S-300 (Pharmacia LKB) gel-filtration chromatography and conjugated to Alexa 488, Alexa 546, or Alexa 633 according to the manufacturer's instructions (Invitrogen). To label cells with Tf, cells were incubated with 20 µg/ml Alexa488/546/633--Tf for 20 min at 37°C to reach steady state.

Labeling cells with lipid analogues
-----------------------------------

MCD--DHE complexes were prepared similarly to a previously described procedure ([@B38]), with minor alterations. In brief, DHE in ethanol was dried under argon and subsequently dissolved in 25 mM MCD in medium 2, making the initial ratio of MCD to DHE 5:1 (mol/mol). The resulting suspension was vortexed and sonicated until it clarified. It was then incubated in a rocking water bath overnight at 37°C and centrifuged at 15,000 × *g* for 10 min before labeling of cells.

Fluorescence recovery after photobleaching
------------------------------------------

Cells were labeled for 1 min with DHE-loaded MCD and chased for 2 h in chase medium to allow for the sterol to equilibrate among membranes. In the last 20 min, the cells were labeled with fluorescent Tf to identify the ERC. A prebleach image was acquired before bleaching. DHE in the ERC was photobleached for 30 s, and images were taken every 30 s for 10 min or every 60 s for 30 min.

DHE efflux assay
----------------

Cells were labeled for 1 min with DHE-loaded MCD and equilibrated for 2 h in chase medium to allow for the sterol to equilibrate among membranes. Cells being imaged were colabeled with 20 µg/ml Alexa 488/546/633--Tf for 20 min at 37°C in chase medium to identify the ERC. An image of the field was taken before the buffer was exchanged for efflux medium. DHE images were taken at 0, 0.5, 1, 3, 5, 10, 20, 30, 40, 50, and 60 min, and the fluorescence in the ERC was measured.

Fluorescence microscopy
-----------------------

Wide-field fluorescence microscopy and digital image acquisition were carried out using a Leica DMIRB microscope with ultraviolet-transmitting epi-illumination and equipped with an Andor iXon^EM^ Blue electron-multiplying charge-coupled device (CCD) camera driven by MetaMorph Imaging System software (Universal Imaging/Molecular Devices, Sunnyvale, CA). All images were acquired using 63×/1.36 numerical aperture (NA) oil-immersion objectives with 2 × 2 pixel binning. DHE was imaged using a filter cube obtained from Chroma Technology (Bellows Falls, VT; 335-nm \[20-nm band pass\] excitation filter, 365-nm long-pass dichromatic filter, and 405-nm \[40-nm band pass\] emission filter). Standard tetramethylrhodamine isothiocyanate, fluorescein isothiocyanate, and Cy5 cubes were obtained from Chroma. Filipin staining was imaged using an A4 filter cube (Leica, Wetzlar, Germany).

Confocal microscopy
-------------------

Cells were imaged on a Zeiss LSM 880 AxioObserver microscope equipped with a Plan-Apochromat oil 63×/1.4 NA differential interference contrast M27 objective. *Z*-stacks were obtained using a step size of 2 μm.

Microinjection
--------------

Cytosolic microinjections were performed using backloaded borosilicate glass capillaries and a Narishige micromanipulator. The microinjection solution was 10 mM HEPES (pH 6.9) and 140 mM KCl with the addition of 0.5 mg/ml rhodamine--dextran and, when indicated, 2.5 mM HPCD. To determine the number of HPCD molecules injected in a single cell, the cellular integrated fluorescence intensity of the coinjected dye, rhodamine--dextran, was compared with a standard curve obtained by imaging rhodamine--dextran in aqueous solutions of known concentrations placed in a hemocytometer chamber. In this way, the number of rhodamine--dextran molecules injected could be calculated, and the number of cellular HPCD molecules was determined based on this. Images of the standard solutions were acquired using imaging parameters identical to those used in microinjection experiments.

Measurement of STARD4 copy number per cell
------------------------------------------

To estimate the number of STARD4 molecules per cell, U2OS-SRA cells were counted and lysed. Proteins from a known fraction of the cell lysate were separated by 16% SDS--PAGE and immunoblotted with anti-STARD4 and anti-actin. Known amounts of purified hSTARD4 were loaded in parallel as standard references. Ten percent of the volume of a lysate of 2.0 × 10^6^ cells was loaded. The band corresponding to STARD4 was quantified and compared with the protein standards. The same measurement was performed with cells expressing GFP-STARD4. In this case, 10% of the cells used for quantification were transfected with GFP-STARD4. The band corresponding to GFP-STARD4 was quantified, from which the number of GFP-STARD4 molecules per cell was calculated.

Free cholesterol measurement by gas chromatography--mass spectrometry
---------------------------------------------------------------------

Cellular lipids were extracted twice with hexane/2-propanol (3:2). During the first extraction, β-sitosterol was added as an internal standard for quantification. Dried lipids were resuspended in hexane and separated on a Varian Factor Four capillary column using a Varian 400 gas chromatography/tandem mass spectrometry system ([@B37]). The protein concentration after solubilization with 0.5 M NaOH was determined by the bicinchoninic acid protein assay.

Transferrin recycling rates
---------------------------

Control and SD4 CRISPR U2OS-SRA cells were labeled with Alexa 488/546--Tf for 20 min. Labeled Tf was chased with 100-fold excess of unlabeled Tf in the presence of 20 μM deferoxamine and fixed at the indicated time points ([@B9]). Cells were imaged as described, and fluorescence intensity was measured for individual cells in multiple fields.

Cholesterol modulation
----------------------

U2OS-SRA cells were grown for 24 h in metabolic depletion medium (McCoy's 5A medium, similar to the growth medium, but with 5% lipoprotein-deficient serum in place of FBS, supplemented with 10 μM mevastatin) to block cholesterol synthesis and deplete cholesterol stores. To overload cholesterol by HPCD treatment, cells were incubated with 10 mM HPCD--cholesterol complex in chase medium for 5 min before labeling.

Energy depletion
----------------

U2OS-SRA cells were labeled with DHE and fluorescent Tf before energy depletion. Cells were incubated with 15 μM sodium azide and 15 μM 2-deoxyglucose for 15 min to deplete cellular ATP before and maintained throughout FRAP and efflux experiments ([@B9]).

STARD4 CRISPR
-------------

Paired single-guide RNAs targeting exon 4 of STARD4 were identified using Geneious software ([www.geneious.com](http://www.geneious.com)), and sequences encoding guide RNAs were cloned into the *Bbs*I sites on PX461 (expressing the Cas9D10A, nickase mutant) according to the published protocol ([www.genome-engineering.org](http://www.genome-engineering.org)). Genomic modifications in transfected cells were assessed using T7 endonuclease assay (M0302; New England Bioscience) after PCR amplification of the target region. Oligonucleotides used for cloning and PCR are listed in [Table 1](#T1){ref-type="table"}.

Mutation detection by SURVEYOR assay
------------------------------------

Cas9-induced mutations were detected using the SURVEYOR Mutation Detection Kit (Transgenomic/IDT). Briefly, an ∼500--base pair region surrounding the expected mutation site was PCR amplified using Herculase II (600675; Agilent Technologies). PCR products were column purified (Qiagen) and subjected to a series of melt--anneal temperature cycles with annealing temperatures gradually lowered in each successive cycle. SURVEYOR nuclease was then added to selectively digest heteroduplex DNA. Digest products were visualized on a 2% agarose gel.

Molecular biology
-----------------

mCherry-FKBP-STARD4 was generated by replacing MTM1 from mCherry-FKBP-MTM1 ([@B8]) via *Not*1 and *Sal*1. Omega-1 loop mutation (W108D) was generated by site-directed mutagenesis. pMito-YFP-FRB ([@B35]) was purchased from Addgene.

Data analysis for FRAP and efflux experiments
---------------------------------------------

In both FRAP and efflux experiments, DHE images were analyzed using MetaMorph Discovery-1 image analysis software ([@B31]; [@B27]). The cell outlines were traced out manually in DHE images. The ERC was also manually outlined for each cell using the Tf-labeled images. We measured the DHE fluorescence intensity from the outlined ERC region (*F^'^*~ERC~) and the entire cell (*F*~cell~), as well as the area of the ERC (*A*~ERC~). Because DHE images were wide-field images, *F^'^*~ERC~ included not only the fluorescence in the ERC but also the fluorescence contributed by the regions of the plasma membrane that were directly above and below the ERC. To calculate the fluorescence contributed by the plasma membrane (*F*~PM\ in\ ERC~) in the ERC region, a small region next to the ERC was selected manually. The integrated fluorescence (*F*~PM~) and the area (*A*~PM~) in this region were measured. We used This was based on the assumption that the DHE fluorescence present on the plasma membrane directly above and below the ERC was similar to that on the plasma membrane next to the ERC. The DHE fluorescence contributed only from the ERC (*F*~ERC~) was calculated using

In FRAP experiments, *F*~ERC~/*F*~cell~ was used to determine the fluorescence recovery ratio. FRAP data were fitted to a single exponential.

In efflux experiments, autofluorescence in the ERC (*F*~auto\ in\ ERC~) was also considered. To calculate *F*~auto\ in\ ERC~, cells without DHE labeling were imaged in parallel experiments. The images were first background corrected for using the fifth percentile of brightness in the image. The ERC was manually outlined for each cell using the Tf-labeled images. Fluorescence power from the outlined ERC region (*F*~auto~) and the area of the ERC (*A*~auto~) was measured. The autofluorescence intensity in the ERC (*I*~auto~) was measured in each cell using

The averaged autofluorescence intensity in the ERC (*I*~aver\ auto~) was calculated from \>20 cells. The DHE fluorescence in the ERC without autofluorescence (*F*~ERC-auto~) was calculated from

*F*~ERC-auto~ at each time point was normalized to *F*~ERC-auto~ at 0 min in each efflux experiment. Efflux data were then fitted to a single-exponential decay. In FRAP and efflux experiments, the half-time in each condition was averaged from multiple cells.
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:   endoplasmic reticulum
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FRAP

:   fluorescence recovery after photobleaching

HPCD
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SRA
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:   StAR--related lipid-transfer
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